Advanced understanding of Staphylococcus aureus and Pseudomonas aeruginosa Infections in EuRopE – Intensive Care Units
ASPIRE-ICU is a prospective, observational, multicenter, epidemiologic cohort study. Nested within routine surveillance among ICU patients in Europe. Aimed at the advanced understanding of Staphylococcus aureus and Pseudomonas aeruginosa infections in Europe (ASPIRE).
Predicting risk of infection during ICU stay
The goal is to estimate the incidence of S. aureus and P. aeruginosa ICU pneumonia, especially ventilator-associated pneumonia (VAP). Another goal is to assess its association with patient-related and contextual factors. For example comorbidities, colonization status, and relevant biomarkers. With this information, a risk prediction model will be developed to quantify the risk of acquiring S. aureus or P. aeruginosa pneumonia during ICU stay.
ASPIRE-ICU will be conducted at some twenty sites in ten European countries. After providing consent, a group of 2000 eligible patients will be enrolled as subjects. Together they form a study cohort where active sampling and more elaborate data collection will take place. Participants will be actively recruited for participation upon ICU admission. And will be followed for a certain period of time to determine the frequency of infections. Samples that will be collected are bacterial isolates and serum samples for in-depth microbiological and immunological testing.
Study team members
Scientist / EFPIA Co-lead / MedImmune
Laboratory Manager / Academic / University of Antwerp
Jr. Project Manager / Academic / UMC Utrecht
Study level information
- Study NO NCT02413242
- Study Name ASPIRE-ICU
- Study Type Observational
- Study Status Active Recruiting
- Enrollment Period 05/15 - 05/18
- Total subjects planned 2000
- Total subjects screened 8355
- Total subjects enrolled 1789
- Total subjects completed 1609
- Light blue
- Preparation phase
- Dark blue
- Trial period
Country level information